- Home
- COLL vs CRMD Comparison
COLL vs CRMD Comparison
Compare COLL & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- CRMD
- Stock Information
- Founded
- COLL 2002
- CRMD 2006
- Country
- COLL United States
- CRMD United States
- Employees
- COLL N/A
- CRMD N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- COLL Health Care
- CRMD Health Care
- Exchange
- COLL Nasdaq
- CRMD Nasdaq
- Market Cap
- COLL 958.8M
- CRMD 865.2M
- IPO Year
- COLL 2015
- CRMD 2010
- Fundamental
- Price
- COLL $32.10
- CRMD $10.72
- Analyst Decision
- COLL Strong Buy
- CRMD Strong Buy
- Analyst Count
- COLL 4
- CRMD 8
- Target Price
- COLL $44.25
- CRMD $17.57
- AVG Volume (30 Days)
- COLL 354.8K
- CRMD 2.6M
- Earning Date
- COLL 11-06-2025
- CRMD 10-29-2025
- Dividend Yield
- COLL N/A
- CRMD N/A
- EPS Growth
- COLL N/A
- CRMD N/A
- EPS
- COLL 1.06
- CRMD 0.79
- Revenue
- COLL $707,007,000.00
- CRMD $121,484,498.00
- Revenue This Year
- COLL $22.23
- CRMD $480.51
- Revenue Next Year
- COLL $2.78
- CRMD $59.81
- P/E Ratio
- COLL $31.21
- CRMD $13.90
- Revenue Growth
- COLL 22.61
- CRMD 14970.29
- 52 Week Low
- COLL $23.23
- CRMD $5.60
- 52 Week High
- COLL $39.95
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- COLL 30.71
- CRMD 37.13
- Support Level
- COLL $34.19
- CRMD $11.05
- Resistance Level
- COLL $35.83
- CRMD $11.71
- Average True Range (ATR)
- COLL 1.05
- CRMD 0.48
- MACD
- COLL -0.33
- CRMD -0.03
- Stochastic Oscillator
- COLL 0.00
- CRMD 0.00
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.